Add to ORKGAbstract: Breast cancer is by far the most frequent cancer in women, worldwide and ranks third overall when both sexes are considered together. For many malignancies, serum tumor markers play an important role in patient management. MUC-1 glycoprotein based serum markers (CA15-3 and CA 27.29) are assays approved by the US Food and Drug Administration for monitoring patients with advanced breast cancer. Potential applications include early detection of recurrent disease and monitoring treatment efficacy in patients with advanced disease. While retrospective data regarding the role of CA27.29 correlates well with progression and treatment of metastatic breast cancer, a multicenter prospective study to further assess the role of CA 27.29 for m...
Introduction:Breast cancer is the most common cancer in women, with 5- and 10-year relative survival...
Background: Metastases are the leading cause of death in patients with breast cancer. The aim of thi...
Aims-To compare the two breast tumour markers, CA15-3 and mucinous-like carcinoma associated antigen...
Background: This study measured blood level of CEA, CA15-3, and CA27-29 markers in different stages ...
In order to define the most useful tumor marker panel in breast cancer patients' follow-up and in mo...
Tumour markers are a potentially powerful means of obtaining information about cancers whilst causin...
Abstracts: The tumor marker CA15.3 is the most specific indicator of breast cancer ever known. CEA a...
In our Country, several circulating glycoproteins as CEA, CA125, CA153, MCA and others are currentl...
The Breast Cancer Mucin (BCM) enzyme immunoassay utilizes two monoclonal antibodies (Mab), M85/34 an...
The role of circulating tumour markers in providing prognostic information has been scarcely studied...
Background: Breast cancer is the most cancer affecting women worldwide and to date most of the inves...
A new tumour marker, mucin-like carcinoma-associated antigen (MCA), was evaluated in 176 breast canc...
In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast...
Two recently developed monoclonal antibody (MAb)-based anti-mucin assays, CA M26 and CA M29, were st...
Tumor response to first-line chemotherapy in advanced breast cancer offers prognostic information an...
Introduction:Breast cancer is the most common cancer in women, with 5- and 10-year relative survival...
Background: Metastases are the leading cause of death in patients with breast cancer. The aim of thi...
Aims-To compare the two breast tumour markers, CA15-3 and mucinous-like carcinoma associated antigen...
Background: This study measured blood level of CEA, CA15-3, and CA27-29 markers in different stages ...
In order to define the most useful tumor marker panel in breast cancer patients' follow-up and in mo...
Tumour markers are a potentially powerful means of obtaining information about cancers whilst causin...
Abstracts: The tumor marker CA15.3 is the most specific indicator of breast cancer ever known. CEA a...
In our Country, several circulating glycoproteins as CEA, CA125, CA153, MCA and others are currentl...
The Breast Cancer Mucin (BCM) enzyme immunoassay utilizes two monoclonal antibodies (Mab), M85/34 an...
The role of circulating tumour markers in providing prognostic information has been scarcely studied...
Background: Breast cancer is the most cancer affecting women worldwide and to date most of the inves...
A new tumour marker, mucin-like carcinoma-associated antigen (MCA), was evaluated in 176 breast canc...
In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast...
Two recently developed monoclonal antibody (MAb)-based anti-mucin assays, CA M26 and CA M29, were st...
Tumor response to first-line chemotherapy in advanced breast cancer offers prognostic information an...
Introduction:Breast cancer is the most common cancer in women, with 5- and 10-year relative survival...
Background: Metastases are the leading cause of death in patients with breast cancer. The aim of thi...
Aims-To compare the two breast tumour markers, CA15-3 and mucinous-like carcinoma associated antigen...